Clinical trial of transcatheter arterial chemoembolization combined with lanreotide and celecoxib in the treatment for hepatocellular carcinoma

Trial Profile

Clinical trial of transcatheter arterial chemoembolization combined with lanreotide and celecoxib in the treatment for hepatocellular carcinoma

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Apr 2016

At a glance

  • Drugs Celecoxib (Primary) ; Lanreotide (Primary) ; Antineoplastics
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Aug 2012 Planned number of patients changed from 100 to 130 as reported by Chinese Clinical Trial Register record (ChiCTR-TRC08000191).
    • 30 Nov 2011 ChiCTR-TRC-08000191 reports trial status as recruiting.
    • 02 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top